Zhiwen Fu

huazhong university of science & technology

H指数:16

被引数:2,124

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Factors associated with cancer pain management behavior among pharmacists: a cross-sectional study based on the COM-B model

基于COM-B模型的药剂师癌症疼痛管理行为相关因素：一项横断面研究

Supportive Care in Cancer

IF3

2026-05-210

PRE

Light-Switched Mesenchymal Stem Cells for In Situ Exosome Amplification in Craniofacial Bone Defect Reconstruction

光控间充质干细胞用于颅颌面骨缺损修复中的原位外泌体扩增

Advanced Science

IF14.1

2026-05-060

OAAI

Gender Differences in EGFR-TKI-Related Adverse Events: A Pharmacovigilance Study Based on the FAERS Database

EGFR-TKI相关不良事件的性别差异：一项基于FAERS数据库的药物警戒研究

Cancer Control

IF0

2026-05-010

PRE

Kaempferol prevents Nrf2 from ubiquitin-mediated proteolysis to mitigate both NLRP3 inflammation and oxidative stress: implications for alleviating DSS-induced colitis in mice

山奈酚通过抑制Nrf2的泛素介导的蛋白降解，以减轻NLRP3炎症和氧化应激：对缓解小鼠DSS诱导的结肠炎的启示

Inflammopharmacology

IF5.3

2025-10-040

PRE

The post-marketing safety of Esketamine among older adults(≥ 65): an real-world pharmacovigilance study

埃斯氯胺胺在老年人群（≥65岁）中的上市后安全性：一项真实世界药物警戒研究

toxicology and applied pharmacology

IF0

2025-08-300

OAAI

Antifungal Activity and Inhibitory Mechanism of Essential Oil from Fresh and Fallen Leaves of Cinnamomum camphora (L.) Presl against Zearalenone-Producing Fusarium graminearum

鲜叶和落叶樟树精油对玉米赤霉烯酮产生菌禾谷镰刀菌的抗真菌活性及抑制机制

LWT

IF0

2025-08-130

Disproportionality Analysis of Renal Adverse Events Associated with a Combination of Immune Checkpoint Inhibitors and Acid-Suppressing Agents-A Pharmacovigilance Study Based on the FAERS Database

免疫检查点抑制剂与抑酸剂联合使用相关肾不良事件的非均衡性分析——一项基于FAERS数据库的药物警戒研究

JOURNAL OF CLINICAL MEDICINE

IF2.9

2025-05-200

A disproportionality analysis of interstitial lung disease associated with drug therapy in spontaneous adverse event reports

药物治疗后间质性肺疾病的非比例数据分析，基于自发不良事件报告

EXPERT OPINION ON DRUG SAFETY

IF3.1

2025-04-170

PRE

QingGan LiDan capsules improved alcoholic liver injury by regulating liver lipid transport and oxidative stress in mice

青甘利胆胶囊通过调节肝脏脂质转运和氧化应激改善小鼠酒精性肝损伤。

FRONTIERS IN PHARMACOLOGY

IF4.8

2025-03-260

The real-world safety profile of empagliflozin: a disproportionality analysis based on the FDA Adverse Event Reporting System (FAERS) database

恩格列净（empagliflozin）的真实世界安全性特征：基于FDA不良事件报告系统（FAERS）数据库的不合理性分析

toxicology and applied pharmacology

IF2.7

2025-02-071

Musculoskeletal adverse events associated with CDK4/6 inhibitors: a real-world study using FDA Adverse Event Reporting System (FAERS) database

与CDK4/6抑制剂相关的肌肉骨骼不良事件：一项基于FDA不良事件报告系统（FAERS）数据库的真实世界研究

toxicology and applied pharmacology

IF2.7

2025-01-290

Diabetic adverse events associated with three commonly used statins: a disproportionality analysis based on the FDA adverse event reporting system database

EXPERT OPINION ON DRUG SAFETY

IF3.1

2024-10-180

PRE

Drug-induced myocarditis: a real-world pharmacovigilance study using the FDA adverse event reporting system database

EXPERT OPINION ON DRUG SAFETY

IF3.1

2024-10-172

PRE

Traditional Chinese medicine for the treatment of cancers of hepatobiliary system: from clinical evidence to drug discovery

中医药治疗肝胆系统肿瘤: 从临床证据到药物发现

MOLECULAR CANCER

IF33.9

2024-10-011

OAAI

Differences in ocular adverse events associated with phosphodiesterase-5 inhibitors: a real-world pharmacovigilance study

与phosphodiesterase-5抑制剂相关的眼部不良事件的差异: 一项真实世界的药物警戒研究

EXPERT OPINION ON DRUG SAFETY

IF3.1

2024-05-162

PRE

Lipocalin 2 (LCN2) confers acquired resistance to almonertinib in NSCLC through LCN2-MMP-9 signaling pathway

PHARMACOLOGICAL RESEARCH

IF10.5

2024-03-011

OAAI

Psychiatric adverse events associated with GLP-1 receptor agonists: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database

FRONTIERS IN ENDOCRINOLOGY

IF4.6

2024-02-0617

OAAI

Biomimetic Nanoplatform for Dual-Targeted Clearance of Activated and Senescent Cancer-Associated Fibroblasts to Improve Radiation Resistance in Breast Cancer

仿生纳米平台用于双靶向清除活化和衰老的癌症相关成纤维细胞以改善乳腺癌的放射抗性

SMALL

IF12.1

2024-01-126

PRE

Incidence and risk of fatal adverse events in cancer patients treated with HER2-targeted antibody-drug conjugates: a systematic review and meta-analysis of randomized controlled trials

BMC CANCER

IF3.4

2023-10-105

OAAI

Gender differences in adverse events related to Osimertinib: a real-world pharmacovigilance analysis of FDA adverse event reporting system

奥希替尼相关不良事件的性别差异: FDA不良事件报告系统的真实世界药物警戒分析

EXPERT OPINION ON DRUG SAFETY

IF3.1

2023-07-317

Zhiwen Fu

个人简介

教育背景

工作经历

荣誉奖项

研究方向